

1AP20 Rec'd PCT/PTO 24 APR 2006

5 **Use of linear poly-alpha-1,4-glucans as resistant starch**

The present invention concerns the use of linear alpha-1,4-glucans as resistant starch (RS) as well as a method for the preparation of resistant starch characterised in that saccharose is reacted with a protein with the
10 enzymatic activity of an amylsucrase.

Fundamentally alpha-amylase resistant starch structures are known as "resistant starch" (RS). RSs are not degraded by alpha-amylases. Owing to their reduced metabolic susceptibility resistant starches represent a
15 reduced energy, bulk-producing component in the sense of a ballast in foodstuffs or foodstuff compositions.

The use of resistant starch (RS) is becoming increasingly important in the foodstuffs industry. The body obtains energy to only a small extent from
20 the degradation of products containing RS. This energy supply affects solely the oxidative degradation of short-chain fatty acids resorbed from the colon. These short-chain fatty acids are the end products of carbohydrate metabolism of the intestinal microflora. With the consumption of foodstuffs containing RS, substrates for the energy metabolism of the
25 intestinal microflora and the colonic epithelial cells are made available. The latter are dependent upon the luminal supply of short-chain fatty acids, especially butyrate, for the maintenance of their structure and function.

High luminal butyrate levels in the colon represent a protective factor against colorectal diseases.

Resistant starch is divided into the following types:

5

RS type 1 Starch not accessible physically to digestion, for example partly milled plant cells (e.g. in muesli).

RS type 2 Indigestible granular starch (starch grains), for example from raw potatoes, green bananas, etc.

10

RS type 3 Indigestible retrograded starch that is obtained, for example, by thermal and/or enzymatic treatment and then retrograded.

15 RS type 4 Indigestible, chemically modified starch that is formed, for example, by cross-bonding or esterification (acetylation, etc).

20 Characteristic of RS type 3 is that it is a resistant starch that is formed by retrogradation. During the retrogradation (also: recrystallisation) of gelatinised starches microcrystalline structures are formed which are not susceptible to enzymatic hydrolysis by alpha-amylases.

25 It is known from US 3,729,380 that the fraction of highly-branched amylopectin can be reduced by enzymatic treatment with debranching enzymes and a such debranched starch possesses a higher tendency to retrogradation than native starch.

30 EP-A1-0 564 893 describes a method for the preparation of an RS-containing product in which an approximately 15% aqueous suspension of

a starch which consists of a minimum of 40% amylose is gelatinised, treated with a debranching enzyme, and the resulting intermediate produced is then retrograded. The product contains at least 15% RS. If in this method a starch with an amylose fraction of 100% is used the product
5 contains about 50% RS.

EP-A1-0 688 872 describes a method for the preparation of a 25 to 50% RS-containing product from a ca. 20% aqueous suspension of a so-called "partially degraded", gelatinised starch or maltodextrin that is enzymatically
10 debranched and retrograded. A starch with an amylose fraction of less than 40 % is used as starting material in the method.

In EP-A1-0 688 872 a starch defined as "partially degraded" is a starch that is reduced in its molecular weight by suitable physical or chemical
15 treatment, whereby the shortening of the chain length affects both amylose and amylopectin. The shortening of the chain length can be carried out both by hydrolytic methods (acid or enzymatically catalysed), and by extrusion, oxidation or pyrolysis. The product obtained by retrogradation of the degraded product is dried by spray drying. The
20 powdered product contains an RS fraction of more than 50% RS.

A retrograded starch is described in EP-A-0846704 that has an RS content of more than 55% and a DSC melting temperature of below 115 °C.
25

The international patent application WO 00/02926-A1 describes a method for the preparation of alpha-amylase resistant polysaccharides wherein water-insoluble poly-alpha-1,4-glucanes are suspended or dispersed in water, the suspension or dispersion obtained is warmed, the paste thus
30 obtained is cooled and the paste is retrograded at a temperature that is

lower than the temperature of the heated paste. In this way RS products are obtained with an RS content of more than 65%.

Schmiedl et al. (Carbohydrate Polymers 43, (2000), 183-193) describe further the butyrogenic action of resistant starches of type 3 (called "resistant starch type III in the publication of Schmiedl et al.) that were prepared from alpha-1,4-glucanes.

The disclosure of the international patent application WO 00/38537-A1 builds on WO 00/02926-A1. WO 00/38537-A1 describes compositions that contain inter alia a resistant starch that is produced as described by the disclosure in WO 00/02926-A1. WO 00/38537-A1 describes that the formation of the resistant starch used in the compositions is carried out by retrogradation of the "non-resistant" water-insoluble linear alpha-1,4-D-glucanes and that the "non-resistant" water-insoluble linear poly-alpha-1,4-D-glucanes produce resistant starches only after retrogradation.

In summary it can be seen that the state of the art for the preparation of non-granular, non-chemically modified resistant starches teaches that resistant starch structures are formed when the polysaccharides are subjected to an additional retrogradation process which is usually time consuming and cost intensive.

The task of the present invention is to make available in cost-effective ways polysaccharides that can be used as resistant starches.

This task is solved by the provision of the embodiments described in the patent claims .

Thus the present invention concerns the use of water-insoluble linear poly-alpha-1,4-D-glucanes as resistant starch (RS).

It was surprisingly found that water-insoluble linear alpha-1,4-D-glucanes
5 can also be used as resistant starches without one or more additional retrogradation steps.

The international patent application WO-00/38537-A1 teaches that a resistant starch obtainable from a water-insoluble linear poly-alpha-1,4-glucan can only be obtained through retrogradation of the "non-resistant"
10 water-insoluble linear alpha-1,4-D-glucans.

It was now surprisingly established that the water-insoluble linear poly-alpha-1,4-glucans described in WO 00/38537-A1 that are used there as
15 starting material for the preparation of resistant starches by means of retrogradation and expressly described there as "non-resistant glucans" themselves surprisingly already represent resistant starches. That is, the present invention makes available in a cost effective manner resistant starches whose preparation needs no time and cost intensive
20 retrogradation step. The omission of the retrogradation step represents a significant advantage opposite the method for the preparation of resistant starches described in WO 00/02926-A1 in which owing to their water insolubility the poly-alpha-1,4-glucans must first be solubilised by high temperatures and/or elevated pressure before they can be made to
25 undergo subsequent retrogradation. The use of elevated temperatures and/or pressures is very energy, and thus cost, intensive.

In connection with the present invention the term "resistant starch" or "RS" is understood to be a polysaccharide that consists of water-insoluble linear
30 poly-alpha-1,4-glucans and is not susceptible to degradation by alpha-

amylases. The "resistant starch" to be used in accordance with the invention is neither a granular starch of RS type 2), nor a retrograded (RS type 3) nor chemically modified starch (RS type 4) and thus represents a new type of resistant starch that consequently will be referred to
5 hereinafter as RS type 5.

In a further embodiment of the use according to the invention the water-insoluble linear poly-alpha-1,4-D-glucans are prepared enzymatically.

10 In a particularly preferred embodiment of the use of the invention the water-insoluble linear poly-alpha-1,4-D-glucans are obtained by the conversion of the aqueous saccharose solution with an enzyme with the enzyme activity of an amylosucrase.

15 In connection with the present invention the term "water-insoluble" is understood to be linear poly-alpha-1,4-D-glucans which according to the definition of the Deutsches Arzneimittelbuch (Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Gori-Verlag GmbH, Frankfurt, 9. Edition (1987) fall within the categories of "less soluble", poorly soluble",
20 "very poorly soluble" and "practically insoluble" in respect of classes 4-7.

The water insolubility of the poly-alpha-1,4-D-glucans used according to the invention is preferably such that at least 98%, in particular at least 99.5% of the polysaccharides used are insoluble in water under normal
25 conditions (temperature = 25 °C +/- 20%'; pressure = 101325 Pascal +/- 20%) (corresponding at least to classes 4 and 5 of the definition of the Deutsches Arzneimittelbuch).

Methods for the determination of the solubility of the of the poly-alpha-1,4-D-glucans are known to the person skilled in the art.
30

In connection with the present invention the term "linear" is understood to be poly-alpha-1,4-D-glucans that exhibit no branching or whose branching is so minimal that it is not detectable with normal methods such as ^{13}C NMR spectroscopy.

In connection with the present invention an "aqueous saccharose solution" is understood to be an aqueous solution which can be free of buffer salts but preferably contains buffer salts, with a saccharose concentration in a range lying between 0.5 wt.% to 80 wt.%, preferably in a range between 5 wt.% - 60 wt.%, further preferred in a range between 10 wt.% - 50 wt.%, especially preferred in a range between 20 wt.% - 30 wt.%.

In connection with the present invention an "enzyme with the activity of an amylosucrase" is understood to be an enzyme that catalyses the following reactions:

1. Saccharose + saccharose \rightleftharpoons oligo-(alpha-1,4-glucan)_n + fructose
2. Oligo-(alpha-1,4-glucan)_n + saccharose \rightleftharpoons poly-(alpha-1,4-glucan)_{n+1} + fructose

Starting from this reaction scheme linear oligomeric or polymeric alpha-1,4-glucans can serve as acceptors for a chain-lengthening reaction that leads to water-insoluble linear poly-alpha-1,4-D-glucans to be used according to the invention whose glucose residues are connected by alpha-1,4-glycosidic bonds and exhibit a mean molecular weight in the range of 0.75×10^2 g/mol to 10^7 g/mol, preferably from 1×10^2 g/mol to 10^5 g/mol, and more preferably from 1×10^3 g/mol to 3×10^4 g/mol, most preferably from 2×10^3 g/mol to 1.2×10^4 g/mol.

These linear oligomeric or polymeric alpha-1,4-glucan acceptors can be added externally, however, they are preferably produced from saccharose by amylosucrase itself as described in example 1.

5

Branching, for example alpha-1,6-glycosidic bonds, are not detectable by ^{13}C NMR (Remaud-Simeon et al. in "Carbohydrate Bioengineering" (ed. S. B. Petersen et al.), Elsevier Science B.V. (1995), 313-320) in these products that were obtained by the reaction of an aqueous saccharose solution with an enzyme with the enzymatic activity of an amylosucrase.

10

In connection with the present invention any optional amylosucrase can be used in principle. Proteins with the enzymatic activity of an amylosucrase are known to the person skilled in the art. Preferably the amylosucrases to be used according to the invention originate from micro-organisms, preferably from bacteria of the genus *Neisseria*, more preferably the amylosucrase from *Neisseria polysaccharea*.

15

The US patent US 6265635-B1, the international patent application WO 00/14249-A1 and Potocki de Montalk et al. (Journal of Bacteriology 181 (2), (1999), 375-381) describe, for example, DNA sequences that code an amylosucrase protein from *Neisseria polysaccharea* that is preferred in connection with the present invention. Further, the presence of proteins with amylosucrase activity have been described for a series of further *Neisseria* species, for example for *Neisseria perflava* (Okada and Hehre, J. Biol. Chem. 249 (1974), 126-135), MacKenzie et al., Can J. Microbiol. 23, (1977), 1303-1307), *Neisseria canis*, *Neisseria cinerea*, *Neisseria denitrificans*, *Neisseria sicca*, *Neisseria subflava* (MacKenzie et al., Can. J. Microbiol. 24, (1978), 357-362).

25

A DNA sequence coding for an amylosucrase protein from *Caulobacter crescentus* CB 15 is described in Complete genome sequence of *Caulobacter crescentus*. (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98:4136-4141, the DNA and protein sequence information is available in the EMBL data bank (<http://srs.ebi.ac.uk>) under ID no. AE005791 and Protein_id AAK23119.1.

An amylosucrase is also known from *Neisseria meningitidis* strain 93246 whose DNA and amino acid sequence is accessible under ID AY099334 and Protein_id AAM51152.1 of the EMBL data bank.

Further, a DNA sequence from *Deinococcus radiodurans* R1 is known (NCBI gene bank accession number NP_294657, known there as alpha-amylase) which codes for a protein with the enzymatic activity of an amylosucrase.

With the help of this DNA and amino acid sequence information of the amylosucrases, preferably with the help of the sequence information described in WO 00/14249-A1 it is now possible for the person skilled in the art to isolate homologous sequences from other organisms, preferably micro-organisms. This can be carried out, for example, with the help of conventional methods, for example by screening genomic banks with suitable hybridisation probes. It is known to the person skilled in the art that the isolation of homologous sequences can also be carried out with the help of (degenerate) oligonucleotides and with the use of PCR-based methods.

The screening of data banks such as are made available, for example, by EMBL (<http://www.ebi.ac.uk/Tools/index/htm>) or NCBI (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/>), can also serve to identify homologous sequences which code for a protein with the

enzymatic activity of an amylosucrase. Here one or more sequences are preset as so-called query. This query sequence is then compared with sequences that are contained in the selected data banks by means of statistical computer programmes. Such data bank interrogations (e.g. blast
5 or fasta searches) are known to the person skilled in the art and can be carried out with different providers.

If such a data bank interrogation is carried at, for example, NCBI (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/>) the standard settings that are preset for the respective comparison query
10 should be used.

These are the settings for protein sequence comparisons (blastp): limit entrez = not activated; filter = low complexity activated; expect value = 10; word size = 3; matrix = BLOSUM62; gap costs: existence = 11, extension = 1.

15 The following parameters are for nucleic acid sequence comparisons (blastn): limit entrez: not activated; filter = low complexity activated; expect value = 10; word size = 11.

In such a data bank search the DNA and amino acid sequence information of the amylosucrases, the sequence information described in WO
20 00/14249-A1 can be used for example as query in order to identify further nucleic acid molecules and/or proteins that code a protein with the enzymatic activity of an amylosucrase.

The enzymatic activity of a protein with amylosucrase activity can be
25 detected very simply by expression of the amylosucrase gene in E. coli and subsequent blue colouration of the E. coli cells with iodine as described, for example, in example 6 of the international patent application WO 95/31553-A1.

In a preferred embodiment of the use according to the patent the conversion of the aqueous saccharose solution is carried out with an enzyme with the enzymatic activity of an amylosucrase *in vitro*.

5 The international applications WO 99/67412-A1 (example 3) (corresponding to US application US 20020052029-A1), WO 00/38537-A1 (example 1) and de Montalk et al. (FEBS letters 471, (2000), 219-223) disclose for example methods for the *in vitro* preparation of poly-alpha-1,4-D-glucans by means of amylosucrase. Explicit reference is made here to
10 the disclosure of these documents. Further, in example 1 of the present patent application an *in vitro* method for the preparation of poly-alpha-1,4-D-glucanes is described.

In a particularly preferred embodiment of the present invention the *in vitro*
15 preparation of poly-alpha-1,4-D-glucans is carried out with a purified amylosucrase. In connection with the present invention a purified amylosucrase is understood to be an enzyme that is essentially free of cell components in which the protein is synthesised. Preferably the term "purified amylosucrase" means an amylosucrase that is free of interfering
20 enzymatic activities (e.g. branching enzyme activities). Preferentially the "purified amylosucrase" has as level of purity of at least 80%, preferably at least 90% and more preferably at least 95%.

Methods for the purification of amylosucrase are known to the person
25 skilled in the art and are described for example in the international patent application WO 99/67412-A1 (example 1).

In a further embodiment of the present invention the *in vitro* preparation of poly-alpha-1,4-D-glucans with amylosucrase takes place in the presence
30 of external linear glucosyl group acceptors. Within the context of the

present invention the term "external linear glucosyl group acceptor" is understood to be a linear oligo- or polysaccharide, for example maltopentaose, maltohexaose, maltoheptaose, that is added externally to the *in vitro* system and is in the position to increase the initial rate of conversion of the saccharose by the amylosucrase.

In a further particularly preferred embodiment of the present invention the *in vitro* preparation of poly-alpha-1,4-D-glucans by means of amylosucrase takes place in the absence of external branched glucosyl group acceptors.

10 Within the context of the present invention the term "external branched glucosyl group acceptor" is understood to be a branched carbohydrate molecule such as glycogen or amylopectin that is added to the *in vitro* system either externally or is already present in the reaction mixture, for example as component of the amylosucrase enzyme extract and that is in the position to increase the initial rate of conversion of the saccharose by the amylosucrase.

In a further embodiment of the use according to the invention the conversion of the aqueous saccharose solution takes place with an enzyme with the enzymatic activity of an amylosucrase *in planta*.

The international patent application WO 95/31553-A1 and the corresponding US patent US 6265635-B1 disclose methods for the *in planta* preparation of poly-alpha-1,4-D-glucans by means of amylosucrase. Explicit reference is made here to the disclosure of this patent application and patent specification.

In a further embodiment of the application of the invention the enzymatic preparation of the poly-alpha-1,4-D-glucanes takes place by an enzyme with the enzymatic activity of an amylomaltase.

In connection with the present invention "amylomaltase" is understood to be an enzyme [E.C.2.4.1.3.] that catalyses the conversion of maltose to maltotriose and glucose and that by removal of the glucose from the reaction equilibrium, for example by oxidation of the glucose, catalyses the synthesis of poly-alpha-1,4-D-glucans (Palmer et al. FEBS Letters 1, (1968), 1-3).

Water-insoluble linear poly-alpha-1,4-D-glucans that exhibit the properties described here (insoluble in water, no branching, molecular weight between 10^2 g/mol and 10^7 g/mol) but prepared by a different method can also be starting materials of the use according to the invention.

In a further embodiment of the use according to the invention the water-insoluble linear poly-alpha-1,4-D-glucans exhibit an RS content determined according to the method of Englyst et al. (European Journal of Clinical Nutrition 46, (Supp.23), (1992), S33-S50) of more than 70 wt.%. In connection with the present invention the method of Englyst et al. preferably used to determine the RS content is described in example 1.

In a further embodiment of the present invention the water-insoluble linear poly-alpha-1,4-D-glucans to be used according to the invention exhibit an RS content determined by the method of Englyst et al. of more than 75 wt.%, preferably more than 80 wt.%, more preferably more than 85 wt.%.

The poly-alpha-1,4-D-glucans to be used according to the invention exhibit high RS contents. That is fully surprising for the person skilled in the art since on the basis of the disclosure content of WO 00/38537-A1 he would have to assume that the poly-alpha-1,4-D-glucans to be used according to

the invention would form "non-resistant" structures, that is, structures that would be susceptible to degradation by alpha-amylases.

5 It was now surprisingly found that contrary to the disclosure of WO 00/38537-A1 the poly-alpha-1,4-D-glucans to be used according to the invention already exhibit RS contents of more than 70 wt.%, preferably more than 80 wt.%, more preferably more than 85 wt.% without them being subjected to an additional retrogradation step.

10 In connection with the present invention "retrogradation" (also: recrystallisation) is understood to mean a process that consists of at least one heating step and at least one cooling step of a polysaccharide suspension or polysaccharide dispersion. During the heating step the polysaccharide suspension or polysaccharide dispersion gelatinises,
15 during the cooling phase microcrystalline structures are formed that are not susceptible to enzymatic hydrolysis by alpha-amylases.

Further it was found that the poly-alpha-1,4-D-glucans to be used according to the invention promote the formation of short-chain fatty acids,
20 particularly butyrate, in the colon and are thus suitable for use as nutritional supplements for the prevention of colorectal diseases.

In a further embodiment of the use according to the invention the water-insoluble linear poly-alpha-1,4-D-glucans exhibit a DSC peak temperature
25 of between 95 °C and 125 °, preferably between 100 °C and 120 °C, more preferably between 105 °C and 116 °C.

The method of "Differential Scanning Calorimetry" (DSC) is known to the person skilled in the art. Results of DSC measurements are used for the
30 characterisation of the thermal stability of the RS products. The DSC

method preferably used in connection with the present invention is described in example 3 of the present patent application.

5 The endothermic peaks of the DSC measurement are more closely characterised by various parameters (T_o , T_p , T_c and dH). The onset temperature T_o characterises the start of the thermal transformation. At the value for T_p (T_p = DSC peak temperature) the temperature at which the maximum thermal transformation of the crystalline material takes place is read off, whereas T_c represent the temperature at which the
10 transformation process is concluded (end temperature.)

The energy of transformation dH (enthalpy of transformation) is determined by calculation of the peak area. It represents the total energy that is necessary for the transformation.

15

In a further embodiment of the use according to the invention the water-insoluble linear poly-alpha-1,4-D-glucans exhibit a DSC energy of phase transformation dH of 10 J/g – 30 J/g, preferably of 11 J/g – 25 J/g and more preferably of 20 J/g – 24 J/g.

20

In a further preferred embodiment of the use according to the invention the water-insoluble linear poly-alpha-1,4-D-glucans are not modified, preferably not retrograded.

25 In connection with the present invention the term "not modified" means that the poly-alpha-1,4-D-glucans to be used according to the invention are produced enzymatically, preferably by conversion of an aqueous saccharose solution by an amylosucrase, and after the enzymatic preparation and isolation of the poly-alpha-1,4-D-glucans are not

ubsequently chemically and/or physically modified, preferably not retrograded.

5 This procedure offers the advantage that cost and time intensive retrogradation steps are omitted unlike the methods for the preparation of resistant starches, in particular RS type 3, described in the state of the art.

10 In a further embodiment the invention concerns the use of slightly branched water-insoluble poly-alpha-1,4-D-glucans as resistant starch.

In connection with the present invention the term "slightly branched" is understood to be a degree of branching of less than 1%, preferably of less than 0.5% and more preferably of less than 0.25%.

15 The determination of the degree of branching is carried out by means of ^{13}C NMR spectroscopy.

20 The branching can occur in positions 2 and 3, preferably in position 6. It can arise by chemical modification, for example by ether formation or esterification or through enzymatic modification, for example with a branching enzyme.

25 The slightly branched water-insoluble poly-alpha-1,4-D-glucans are preferably not modified, more preferably not retrograded.

In a further embodiment the present invention concerns a method for the preparation of resistant starch encompassing the following process steps:

- a) preparation of an aqueous saccharose solution;

- b) conversion of the aqueous saccharose solution with a protein with the enzymatic properties of an amylosucrase into water-insoluble linear poly-alpha-1,4-D glucans; and optionally
- c) isolation of water-insoluble linear poly-alpha-1,4-D-glucans.

5

The preparation of an aqueous saccharose solution is known to the person skilled in the art. Suitable aqueous saccharose solutions have already been described in connection with the use according to the invention.

The conversion according to process step b) has also already been described above in connection with the use according to the invention.

Methods are also known to the person skilled in the art how he can isolate the water-insoluble linear poly-alpha-1,4-D-glucans that are resistant starches RS type 5. The properties of the water-insoluble linear poly-alpha-1,4-D-glucans to be used according to the invention have already been described above in connection with the use according to the invention.

In a further embodiment of the present invention the water-insoluble linear poly-alpha-1,4-D-glucans can be dried after isolation. They can be for example freeze dried, air dried or spray dried.

In a further embodiment the present invention concerns the use of the method of the invention for the preparation of resistant starch.

The following examples serve to illustrate the invention more closely without it being limited to the examples.

General methods

1. Preparation of water-insoluble linear poly-alpha-1,4-D-glucans.

The preparation of water-insoluble linear poly-alpha-1,4-D-glucans is described for example in WO 00 44492, WO 00 02926, WO 00 38537, WO 99 67412 or WO 01 42309.

2. Purification of amylosucrase

A protocol for the purification of a protein with the enzymatic activity of an amylosucrase is described in WO 99 67412.

3. Expression of a protein with the enzymatic activity of an amylosucrase

The expression of a protein with the enzymatic activity of an amylosucrase in bacterial cells is described i.a. by Potocki de Montalk et al. (2000, FEMS Microbiology Letters 186, 103-10) and Potocki de Montalk et al. (1999, J. of Bacteriology 181,357-381).

20 Example 1

Determination of the RS content of water-insoluble linear poly-alpha-1,4-D-glucans

The RS content of water-insoluble linear poly-alpha-1,4-D-glucans, prepared by the conversion of saccharose by a protein with the enzymatic activity of an amylosucrase, was based upon the method of Englyst (European Journal of Clinical Nutrition (1992) 46 (suppl.2), p.33-50) for the determination of resistant starches Type III. At the same time the method of Englyst was modified in correspondence with the information on the determination of RS content in WO 00 02926.

a) Pancreatine/amyloglucosidase (AGS) treatment

Pancreatine/amyloglucosidase digestion buffer used:

5

0.1 M Na acetate pH 5.2

4 mM CaCl₂

Preparation of the enzyme solution:

10 12g pancreatine (Merck, Product no. 1.07130.1000) were stirred in 80 ml demineralised water (conductivity ca. 18 M ohm) for 10 min at 37 °C and then centrifuged for 10 min at 3000 rpm.

54 ml of the supernatant obtained after centrifugation were treated with 9.86 ml demineralised water and 0.14 ml amyloglucosidase (6000 u/ml, 15 Sigma, Product no. A-3042).

Pancreatine/amyloglucosidase (AGS) digestion procedure

5 assays of the pancreatine/amyloglucosidase (AGS) digestion are prepared each time for each batch of water-insoluble linear poly-alpha-1,4- 20 D-glucan to be measured. No enzyme solution is later added to 2 of each of these 5 assays. The assays to which no enzyme solution is added are designated as reference and are used for determination of the recovery rate. The remaining 3 assays are designated as sample, later treated with enzyme solution and used for the determination of the RS content of the 25 respective water-insoluble linear poly-alpha-1,4-D-glucans.

A number of reaction vessels which contain no water-insoluble linear poly-alpha-1,4-D-glucans were processed in parallel (blank samples). These blank samples which contain no linear water-insoluble poly-alpha-1,4-D-glucan are used for the determination amount of co-precipitated material 30 (protein, salts).

The tare weight of 50 ml reaction vessels (Falcon tubes) was determined and then in each case ca. 200 mg of the water-insoluble linear poly-alpha-1,4-D-glucan are weighed in.

- 5 15 ml Na acetate buffer was added to each of the linear water-insoluble poly-alpha-1,4-D-glucan samples and the blanks samples, and 20 ml Na acetate buffer to each of the references (see above). These samples were pre-warmed to 37 °C.

- 10 The reaction was initiated by the addition of 5 ml enzyme solution to each of the individual reaction vessels of the samples and the blank samples which were then shaken for 2 hours at 37 °C (200 rpm).

The reaction was quenched by the addition of 5 ml glacial acetic acid (equilibrated to pH 3.0) and 80 ml technical ethanol to the samples, blank samples and the references.

- 15 Precipitation of the water-insoluble linear poly-alpha-1,4-D-glucan from the reaction mixture was achieved by incubation of the quenched reaction assay at room temperature for 1 hour.

- After sedimentation (centrifugation for 10 min at 2500 x g) the sediment of the individual assays obtained was washed twice with 80% ethanol to
20 remove short-chain glucans and then freeze dried after cooling to -70 °C.

The samples were re-weighed and the weight differences used for the calculation of the "gravimetric" RS content.

b) Determination of the RS content

- 25 The following procedure was used for the determination of RS content of the individual batches of water-insoluble linear poly-alpha-1,4-D-glucans:

- a) Determination of the water content of the individual sample batches of linear poly-alpha-1,4-D-glucans (wt.H₂O)

- b) Determination of the tare weight of the individual reaction vessels for the respective samples (wt.RGP), references (wt.RGR) and the blank samples (wt.RGB).
- 5 c) Weighing ca. 200 mg of water-insoluble linear poly-alpha-1,4-D-glucan into the individual reaction vessels for samples (wt.P) and references (wt.R)
- d) Calculation of the dry fraction of the weights for samples ($\text{wt.P}_{\text{tr}} = \text{wt.P} - \text{wt.H}_2\text{O}$) and references ($\text{wt.R}_{\text{tr}} = \text{wt.R} - \text{wt.H}_2\text{O}$)
- 10 e) Enzymatic digestion of the respective samples and blank samples. References are treated in the same way but without addition of the enzyme solution.
- f) Precipitation, sedimentation, washing and freeze drying of the substances remaining in the reaction vessels of the samples, references and blank samples after the treatment described in e).
- 15 g) Weighing of the substances remaining in the reaction vessels of the samples (wt.PRg), references (wt.RRG) and blank samples (wt.BRG), inclusive of reaction vessel after the treatment described in f).
- 20 h) Calculation of the weight of the substances remaining in the reaction vessels of the samples ($\text{wt.P}_{\text{nv}} = \text{wt.PRg} - \text{wt.RGP}$), references ($\text{wt.R}_{\text{nv}} = \text{wt.RRG} - \text{wt.RGR}$) and the blank samples ($\text{wt.B}_{\text{nv}} = \text{wt.BRG} - \text{wt.RGB}$) after the treatment described under f).
- 25 i) Determination of the water content of the substances remaining in the reaction vessels of samples ($\text{wt.H}_2\text{O}_{\text{Pnv}}$), references ($\text{wt.H}_2\text{O}_{\text{Rnv}}$) and the blank samples ($\text{wt.H}_2\text{O}_{\text{Bnv}}$) after the treatment described under f).
- 30

- j) Calculation of the dry fraction of the substances remaining in the reaction vessels of the samples ($\text{wt.Pnv}_{\text{tr}} = \text{wt.Pnv} - \text{wt.H}_2\text{OPnv}$) references ($\text{wt.Rnv}_{\text{tr}} = \text{wt.Rnv} - \text{wt.H}_2\text{ORnv}$) and the blank samples ($\text{wt.Bnv}_{\text{tr}} = \text{wt.Bnv} - \text{H}_2\text{OBnv}$) after the treatment described under f).
- k) Determination of the corrected weights for the samples ($\text{wt.Pnv}_{\text{kor}} = \text{wt.Pnv}_{\text{tr}} - \text{wt.Bnv}_{\text{tr}}$) and references ($\text{wt.Rnv}_{\text{kor}} = \text{wt.Rnv}_{\text{tr}} - \text{wt.Bnv}_{\text{tr}}$)
- l) Calculation of the percentage fraction of the corrected weights of the water-insoluble linear poly-alpha-1,4-D-glucans remaining after enzymatic digestion relative to the dry weight of the starting amount of the samples ($\text{RSaP} = \text{wt.Pnv}_{\text{kor}} / \text{wt.P}_{\text{tr}} \times 100$) and calculation of the percentage fraction of the corrected weights of the remaining water-insoluble linear poly-alpha-1,4-D-glucans of the references relative to the dry weight of the starting amounts of the references ($\text{RSaR} = \text{wt.Rnv}_{\text{kor}} / \text{wt.R}_{\text{tr}} \times 100$).
- m) Determination of the mean value of the percentage fractions of the water-insoluble linear poly-alpha-1,4-D-glucans remaining after enzymatic digestion of the samples ($\text{RSaPMW} = n \times \text{RSaP} / n$) and determination of the mean values of the percentage fractions of the remaining water-insoluble linear poly-alpha-1,4-D-glucans of the references: (recovery rate; $\text{RSaRMW} = n \times \text{RSaR} / n$) where n is the number of sample and reference assays carried out for the respective batches of water-insoluble linear poly-alpha-1,4-D-glucans.
- n) Determination of the percentage RS content of the individual batches of water-insoluble linear poly-alpha-1,4-D-glucans by correction of the mean values of the percentage fractions of the

water-insoluble linear poly-alpha-1,4-D-glucans remaining after enzymatic digestion with the recovery rate ($RS = RS_{SaPMW} / RS_{SaRMW} \times 100$).

5 c) RS content of the water-insoluble linear poly-alpha-1,4-D-glucans

The RS content of water-insoluble linear poly-alpha-1,4-D-glucans, prepared by the conversion of saccharose by a protein with the enzymatic activity of an amylosucrase was determined according to the method described under example 2b). If a crude protein extract from *E. coli* bacterial strain DH5 α that expresses a nucleic acid sequence coding an amylosucrase from *Neisseria polysaccharea* (Potocki de Montalk et al., 1999, J. of Bacteriology 181, 357-381) was used for the preparation of the water-insoluble linear poly-alpha-1,4-D-glucan the RS content of the water-insoluble linear poly-alpha-1,4-D-glucan was 75% +/- 2%.

If a crude protein extract of the *E. coli* bacterial strain KV832 (Kiel et al., 1987, Mol. Gen. Genet. 207: 294-301) that expresses a nucleic acid sequence coding an amylosucrase from *Neisseria polysaccharea* (Potocki de Montalk et al., 1999, J. of Bacteriology 181, 357-381) was used for the preparation of the water-insoluble linear poly-alpha-1,4-D-glucan the RS content of the water-insoluble linear poly-alpha-1,4-D-glucan was 91% +/- 2%.

25

30

Example 2**Determination of the molecular weight of water-insoluble linear poly-alpha-1,4-D-glucans**

- 5 The molecular weight of water-insoluble linear poly-alpha-1,4-D-glucans prepared by the conversion of saccharose by a protein with the enzymatic activity of an amylosucrase was determined by gel permeation chromatography (GPC).
- 10 a) Preparation of the samples for carrying out the GPC
1. Preparation of a 1% solution of the water-insoluble linear poly-alpha-1,4-D-glucan in DMSO+90 mM NaNO₃ (= corresponds to the eluent used in the GPC analysis)
 2. Shake for ca. 30 minutes at 60 °C to dissolve
 - 15 3. Centrifugation for 1 minute at 8000 rpm on a bench centrifuge
 4. 1:10 dilution in the eluent
 5. Injection of 24 µl 1:10 dilution

b) GPC analysis

- 20 Components of the GPC system used:
- Pump: Dionex, P580
- Autosample: Dionex, AS50
- Columns: PSS (pre-column: PSS GRAM, 10 µ; separation columns: PSS GRAM 3000, 10 µ and PSS GRAM 100, 10 µ
- 25 column oven: Dionex, model 585
- detection: Shodex R171

The GPC analysis was carried out under the following conditions:

Autosampler and column oven at 60 °C

Eluent: DMSO + 90 mM NaNO₃

Eluent flow rate: 0.7 ml/min

The control was carried out with the software Chromeleon (Dionex) and the evaluation of the data with the help of the software PSS WinGPC
5 compact V.6.20.

c) Molecular weights of the water-insoluble linear poly-alpha-1,4-D-glucans

The water-insoluble linear poly-alpha-1,4-D-glucans investigated exhibited
10 a molecular weight of 1500 to 55,000 Dalton. The peak maximum lay at 9000 Dalton.

Example 3

15 **Determination of the thermal stability of the water-insoluble linear poly-alpha-1,4-D-glucans by means of DSC analysis**

The thermal stability of the RS products was determined with the aid of the Pyris Diamond DSC from Perkin Elmer. 10 mg each time of RS products
20 were weighed into a measurement capsule (steel pan Perkin Elmer product no. 03190029), treated with 30 µl deionised water (Millipore) and the measurement capsule was sealed as according to the producer's instructions. All samples were measured within 12 hours. An empty measurement capsule served as reference. Calibration was carried out
25 with an indium standard. The DSC measurement were carried out over a temperature range of 20-150 °C at a heating rate of 10 °C per minute. The determination of T₀, T_p and ΔH was carried out with Pyrus software (vers. 5). The data for ΔH relate to the dry weights of the samples which were

determined with a heated balance. Each sample was measured twice by this method.

	<i>E. coli</i> DH5 α Freeze drying	<i>E. coli</i> KV832 Freeze drying	<i>E. coli</i> KV832 Air drying
T ₀	78.3 °C	98.7 °C	92.7 °C
T _P	101.3 °C	112.3 °C	114.2 °C
ΔH	12.4 J/g	23 J/g	20 J/g

5 **Table 1:** Values determined by DSC analysis for water-insoluble linear poly-alpha-1,4-D-glucans

Water-insoluble linear poly-alpha-1,4-D-glucans were prepared either with a crude protein extract of *E. coli* bacterial strain DH5 α that expresses a
 10 nucleic acid sequence coding an amylosucrase from *Neisseria polysaccharea* (Potocki de Montalk et al., 1999, J. Bacteriology 181, 357-381) or with a crude protein extract of *E. coli* bacterial strain KV832 (Kiel et al., 1987 Mol. Gen. Genet. 207: 294-301) that expresses a nucleic acid sequence that codes for an amylosucrase from *Neisseria polysaccharea*
 15 (Potocki de Montalk et al., 1999, J. Bacteriology 181, 357-381). The water-insoluble linear poly-alpha-1,4-D-glucans obtained were either freeze dried or air dried.

Patent claims

- 5 1. Use of water-insoluble linear poly-alpha-1,4-D-glucans as resistant starch (RS).
- 10 2. Use according to claim 1 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans were obtained by the reaction of an aqueous saccharose solution with an enzyme with the enzymatic activity of an amylosucrase.
- 15 3. Use according to claim 2 characterised in that the reaction of the aqueous saccharose solution is carried out with an enzyme with the enzymatic activity of an amylosucrase *in vitro*.
- 20 4. Use according to claim 2 characterised in that the reaction of the aqueous saccharose solution is carried out with an enzyme with the enzymatic activity of an amylosucrase *in planta*.
- 25 5. Use according to one of the claims 1 to 4 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans exhibit an RS content determined by the method of Englyst et al. of more than 70 wt.%.
6. Use according to one of claims 1 to 5 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans exhibit a DSC peak temperature of between 95 °C and 125 °C.

7. Use according to one of the claims 1 to 6 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans have a mean molecular weight of 1×10^2 g/mol to 10^5 g/mol.
- 5 8. Use according to one of the claims 1 to 6 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans have a mean molecular weight of 1×10^3 g/mol to 3×10^4 g/mol.
- 10 9. Use according to one of the claims 1 to 6 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans have a mean molecular weight of 2×10^3 g/mol to 1.2×10^4 g/mol.
- 15 10. Use according to one of the claims 1 to 9 characterised in that the water-insoluble linear poly-alpha-1,4-D-glucans were not retrograded.

INTERNATIONAL SEARCH REPORT

national Application No

PCT/EP2004/012090

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C08B30/12 C08B37/00 A23L1/09 A23L1/0522

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08B A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/094172 A1 (BENGIS HOLGER ET AL) 22 May 2003 (2003-05-22) cited in the application claims 1,8,9,11-15; examples 6-9; tables 1-3	1-10
X	US 2003/004332 A1 (BAUERLEIN MICHAEL ET AL) 2 January 2003 (2003-01-02) cited in the application claims; examples	1-9
X	DE 198 60 375 A (AVENTIS RES & TECH GMBH & CO) 6 July 2000 (2000-07-06) cited in the application claims	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

18 January 2005

Date of mailing of the international search report

28/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smeets, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/012090

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 2003094172	A1	22-05-2003	DE	19959863 A1	13-06-2001
			AU	1862901 A	18-06-2001
			WO	0142309 A2	14-06-2001
			EP	1242461 A2	25-09-2002
			JP	2003516433 T	13-05-2003
US 2003004332	A1	02-01-2003	DE	19830618 A1	13-01-2000
			AT	253595 T	15-11-2003
			AU	763977 B2	07-08-2003
			AU	4610599 A	01-02-2000
			CA	2333383 A1	20-01-2000
			CN	1307591 T	08-08-2001
			DE	59907641 D1	11-12-2003
			WO	0002926 A1	20-01-2000
			EP	1095063 A1	02-05-2001
			JP	2002520425 T	09-07-2002
DE 19860375	A	06-07-2000	DE	19860375 A1	06-07-2000
			AT	273622 T	15-09-2004
			AU	1387800 A	31-07-2000
			DE	59910308 D1	23-09-2004
			DK	1139789 T3	11-10-2004
			WO	0038537 A1	06-07-2000
			EP	1139789 A1	10-10-2001
			JP	2002533107 T	08-10-2002